[The circadian effects of antiglaucomatous drugs].
OBJECTIVE
To collect data reflecting the current knowledge on the interactions of medical antiglaucomatous therapy and circadian variations.


METHODS
Review of the available literature published on this topic in common electronic databases.


RESULTS
The IOP-reducing effect of a molecule throughout the day depends on many parameters and still remains poorly investigated. It is well known that beta-blockers have a poor efficacy at night, while prostaglandins prevent nocturnal IOP variations because of their original mechanism.


CONCLUSIONS
The lack of a 24-hour IOP recording device limits our ability to track the effect of antiglaucomatous drugs over 24 hours, an important point because these antiglaucomatous drugs vary in terms of their capacity to reduce IOP over a 24-hour period.


CONCLUSIONS
Assessing the effect of antiglaucomatous therapy on a 24-hour basis remains very difficult. However, in the next few Years, this could become an emerging focus point in the management of glaucoma.
Service d'Ophtalmologie, CHU de Dijon, Hôpital Général, 3, rue du Faubourg Raines, B.P. 1519, 21033 Dijon Cedex, France. Alain.bron@CHU-Dijon.fr
A
A
Bron
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D001082:Aqueous Humor / Q000378:metabolism; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D019454:Chronotherapy; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology*; D014644:Genetic Variation; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects / Q000502:physiology*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D010277:Parasympathomimetics / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D011465:Prostaglandins, Synthetic / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D013566:Sympathomimetics / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D010277:Parasympathomimetics; D011465:Prostaglandins, Synthetic; D013566:Sympathomimetics